Cohance Lifesciences

BSE: 543064 21 Feb 2026

Healthcare

₹ 350.1 ▼ -1.39%

SUVEN PHARMACEUTICALS LIMITED specializes in Pharmaceuticals within the Healthcare sector.

Cohance Lifesciences

BSE: 543064 21 Feb 2026

Healthcare

₹ 350.1 ▼ -1.39%

SUVEN PHARMACEUTICALS LIMITED specializes in Pharmaceuticals within the Healthcare sector.

High

358.25

Low

358.25

Open

358.25

Prev Close

355.05

Market Cap

11716.12 Cr

Cohance Lifesciences - Share Price & Details

Market Cap

₹ 11,716.12

WAP

306.28

Turnover

25.60(Cr.)

TTQ

8.36(Lakh)

2 Week Avg Qty

2.09(Lakh)

Circuit Limit

8,36,128.00/244.40

Stock P/E

94.6

Book Value

₹66.6

Dividend Yield

0.0

ROCE

14.9

ROE / PB

10.81 / 5.31

Face Value

1.00

PEG Ratio

-5.84

EVEBITDA

₹54.0

Debt

279

CMP / FCF

157.0

Debt to equity

₹0.16

NP Ann

265

High price all time

1,360

Piotroski score

₹4.0

Graham Number

137.0

No. Eq. Shares

38.3

Net CF

₹38.2

Net profit

329

Price to book value

13.0

Interest Coverage

₹18.8

Low price all time

87.0

Industry PE

33.0

Reserves

₹1,671

Free Cash Flow

₹132

Broker Recommendations

Date	Author	Type	Reco Price	Target Price	Potential	Source	PDF Link
13 Nov 2025	ICICI Securities	Sell	₹629.5	₹640	7.3%	moneycontrol	View
29 May 2025	ICICI Securities	Buy	₹1,107.75	₹1,365	27.9%	moneycontrol	View
25 Mar 2025	ICICI Securities	Buy	₹1,173.95	₹1,400	21.6%	moneycontrol	View
29 Feb 2024	Geofin Comtrade	Sell	₹630.9	₹571	-55.7%	moneycontrol	View

Price Chart

Volume Chart

Peer Comparison

Stock	Total Income	Net Profit	Net Sales	EPS	Market Cap (in Cr)	P/E
Fabino Enterprises Ltd	NA	NA	NA	NA	5.09	84.8
Triochem Products Ltd	2.21	-1.32	NA	-5.38	0
Cohance Lifesciences Limited	5507.1	290.2	5445.5	0.96	33,257	94.6
Aster DM Healthcare Limited	6971.6	551.6	6657.5	1.07	32388	91.6
Gland Pharma Limited	17,585.36	2,614.75	16,953.63	15.87	32261	41.9

Peer Comparison Chart

About Cohance Lifesciences

SUVEN PHARMACEUTICALS LIMITED, with Security Code 543064, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.

Order Book

Latest News

Suven Pharmaceuticals Limited (SUVENPHAR)’s Trend in 2025 - High-performance investment picks

(04 Aug 2025)

Suven Pharmaceuticals Limited (SUVENPHAR)'s Trend in 2025 ✌️【Stock Analysis】✌️ Tired of following the crowd? Our analysts specialize in...

Suven Pharmaceuticals Limited (543064)’s Trend in 2025 - Free Stock Chart Pattern Guide

(30 Jul 2025)

Suven Pharmaceuticals Limited (543064)'s Trend in 2025 ✌️【Market Discussions】✌️ Our platform integrates global futures, commodity,...

Suven Pharmaceuticals Limited (SUVENPHAR) Stock Rallies - Free Trend-Following Techniques

(24 Jul 2025)

Suven Pharmaceuticals Limited (SUVENPHAR) Stock Rallies ✌️【Stock Buzz】✌️ Our expert-picked stocks have delivered over 200% returns...

Bullish Pattern Emerging on Suven Pharmaceuticals Limited (543064) - Breakout stock performance

(24 Jul 2025)

Bullish Pattern Emerging on Suven Pharmaceuticals Limited (543064) ✌️【Stock Observations】✌️ Target more than 200% capital growth with...

Where Could Suven Pharmaceuticals Limited (543064) Be Headed - Free Stock Market Forecast Reports

(24 Jul 2025)

Where Could Suven Pharmaceuticals Limited (543064) Be Headed ✌️【Growth Stocks】✌️ Receive stock alerts backed by real data and expert...

Where Could Suven Pharmaceuticals Limited (SUVENPHAR) Be Headed - Spectacular growth rates

(23 Jul 2025)

Where Could Suven Pharmaceuticals Limited (SUVENPHAR) Be Headed ✌️【Market Watch】✌️ Stock group predictions and real-time quotes for global...

Quarterly Table

Standalone Consolidated

Metrics	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Sales	212.8	243.5	222.1	236.1	275.4	330.2	483.6	0.0
Expenses	144.7	171.4	139.1	135.1	159.9	262.9	379.4	-36.4
Operating Profit	68.1	72.1	83.0	101.0	115.5	67.3	104.2	36.4
OPM %	32.02%	29.63%	37.39%	42.79%	41.93%	20.37%	21.55%	0%
Other Income	14.0	16.9	18.0	13.4	15.2	6.6	5.0	0.0
Interest	1.3	2.3	1.6	1.5	2.6	2.3	6.8	5.2
Depreciation	11.3	15.7	12.0	12.3	13.4	15.2	31.4	31.2
Profit before tax	69.5	71.1	87.4	100.7	114.6	56.4	79.1	0.0
Tax %	-24.7%	-24.8%	-25.5%	-24.2%	-24.7%	-21.1%	26%	0%
Net Profit	52.4	53.4	65.1	76.3	86.4	44.3	52.6	0.0
EPS in Rs	2.06	2.1	2.56	2.98	3.37	0	1.37	0

Metrics	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Dec 2025	Dec 2025	Dec 2025
Sales	252.9	230.7	257.7	307.2	402.0	544.6	544.6	544.6
Expenses	179.6	150.8	153.7	189.5	328.4	449.2	449.2	449.2
Operating Profit	73.3	79.9	104.0	117.7	73.7	95.4	95.4	95.4
OPM %	29%	34.64%	40.36%	38.32%	18.32%	17.51%	17.51%	17.51%
Other Income	17.1	18.2	14.1	15.7	10.6	1.3	1.3	1.3
Interest	2.3	1.6	1.7	3.3	5.8	9.1	9.1	9.1
Depreciation	17.2	13.4	17.0	20.4	26.8	46.9	46.9	46.9
Profit before tax	70.9	83.1	99.5	109.7	51.7	45.5	45.5	45.5
Tax %	-24.7%	26.9%	17.6%	24.1%	-24.8%	28.5%	28.5%	28.5%
Net Profit	53.4	60.8	82.0	83.3	38.7	29.0	29.0	29.0
EPS in Rs	2.1	2.39	3.21	3.23	0	0.96	0.96	0.96

Shareholding Distribution

Shareholding Pattern

Compounded Data

Consolidated

Standalone

Compounded Sales Growth
10 Years:	0%
5 Years:	22%
3 Years:	1%
TTM:	-15%

Compounded Profit Growth
10 Years:	0%
5 Years:	20%
3 Years:	-4%
TTM:	-26%

Stock Price CAGR
10 Years:	0%
5 Years:	46%
3 Years:	27%
1 Year:	71%

Compounded Sales Growth
10 Years:	0%
5 Years:	23%
3 Years:	1%
TTM:	-10%

Compounded Profit Growth
10 Years:	0%
5 Years:	20%
3 Years:	-9%
TTM:	-25%

Stock Price CAGR
10 Years:	0%
5 Years:	46%
3 Years:	27%
1 Year:	71%

All Deals

Date	Stock	Party	Deal	Acq. Mode	Trans.	Quan.	Price	Value

Stock Mutual Funds Data

Order Book

News Date ▲▼	Headline ▲▼	Issuer Entity ▲▼	Issuer Type ▲▼	Order Size ▲▼	Time Period ▲▼
Loading company updates…

Loading technicals…

Moving Averages

Latest Close: — • Records Used: — • Last Trading Date: —

Simple Moving Averages (SMA)

Period	SMA Value	Status

Exponential Moving Averages (EMA)

Period	EMA Value	Status

Oscillators

Key Oscillators

latest calculation

Indicator	Value

Cohance Lifesciences

Cohance Lifesciences

Cohance Lifesciences - Share Price & Details

Broker Recommendations

Price Chart

Volume Chart

Peer Comparison

Peer Comparison Chart

About Cohance Lifesciences

Order Book

Latest News

Suven Pharmaceuticals Limited (SUVENPHAR)’s Trend in 2025 - High-performance investment picks

Suven Pharmaceuticals Limited (543064)’s Trend in 2025 - Free Stock Chart Pattern Guide

Suven Pharmaceuticals Limited (SUVENPHAR) Stock Rallies - Free Trend-Following Techniques

Bullish Pattern Emerging on Suven Pharmaceuticals Limited (543064) - Breakout stock performance

Where Could Suven Pharmaceuticals Limited (543064) Be Headed - Free Stock Market Forecast Reports

Where Could Suven Pharmaceuticals Limited (SUVENPHAR) Be Headed - Spectacular growth rates

Suven Pharmaceuticals Limited (SUVENPHAR)’s Trend in 2025 - Rapid wealth multiplication

Suven Pharmaceuticals renamed as Cohance Lifesciences

Suven Pharmaceuticals Faces Short-Term Decline Amid Long-Term Growth Resilience

JSA advises on $3 billion Suven Pharma–Cohance Lifesciences merger

Cohance Lifesciences Ltd | Stock Share Price Live

JSA Advises Advent International and Suven Pharmaceuticals on USD 3 Billion Merger with Cohance Lifesciences

Suven Pharmaceuticals is now Cohance Lifesciences

Suven Pharmaceuticals rebrands as Cohance Lifesciences

Cohance Lifesciences, The New Identity Of Suven Pharmaceuticals

Suven Pharma rebranded as Cohance Lifesciences

Suven Pharmaceuticals Faces Bearish Trend Amid Broader Market Fluctuations

Merger of Suven Pharma, Cohance Lifesciences to take effect from May 1

Its official: Suven Pharma and Cohance Lifesciences merger to take effect from May 1

Its official: Suven Pharma and Cohance Lifesciences merger to take effect from May 1 - Industry News

'Sense of urgency' among pharma giants to move beyond China: Suven Pharma Chairman

I-Sec initiates coverage on Suven Pharmaceuticals with a Buy rating, target price Rs 1,400

NCLT approves amalgamation of Suven Pharma, Cohance Lifesciences

NCLT sanctions amalgamation of Cohance Lifesciences into Suven Pharmaceuticals

NCLT approves scheme of amalgamation of Cohance Lifesciences, Suven Pharmaceuticals

NCLT approves amalgamation of Cohance Lifesciences into and with Suven Pharmaceuticals

Trade Pick for Today: A mid-cap pharma stock for almost 6% gain

Suven Pharma reports strong Q3; net profit jumps 77%, revenue surges 40%

Suven Pharma Q3 Results: Net profit surges 78% to Rs 83 crore, revenue up 40%

Suven Pharmaceuticals Ltd. - 3 stocks closed above VWAP on December 26

Suven Pharmaceuticals Rises 3.03% After Six Days of Decline on December 26, 2024

Suven Pharmaceuticals Limited completed the acquisition of 56% stake in NJ BIO, Inc.

Suven Pharmaceuticals Reports 5.64% Stock Decline Amid Broader Market Gains

Suven Pharmaceuticals acquires 56% stake in NJ Bio for ₹53 cr | Tap to know more | Inshorts

SUVEN PHARMACEUTICALS Share Price Today Down 6%

Intellect Design Arena, Suven Pharma, India Cements, Zomato, Sterling and Wilson Renewable Energy, ITC: Check top buzzing stocks of the day

Suven Pharma sets sights on M&As to scale up tech expertise & order book

Suven Pharma picks up controlling stake in NJ Bio for ₹535 Crore

Stocks To Watch: Tata Power, Godrej Consumer Products, Welspun Corp, Suven Pharma, Delta Corp, Paytm, Easy Trip Planners

Stocks to Watch: Suven Pharma, Reliance Power, Laurus Labs, Paytm, and more | Stock Market News

Advent-owned Suven Pharma to buy majority stake in NJ Bio for $64 mn

Stocks in news: Wipro, Paytm, RITES, Welspun Corp, CEAT, Biocon, JSW Energy & Suven Pharma

Stocks to Watch: Suven Pharma, Reliance Power, Laurus Labs, Paytm, and more

Suven to acquire 56% stake in ADC specialist NJ Bio for US$64.4 million

Suven Pharma acquires 56% stake in US-based NJ Bio

Suven Pharmaceuticals acquires controlling stake in US-based NJ Bio

Suven Pharma acquires majority stake in US-based NJ Bio

Suven Pharmaceuticals to acquire majority stake in US based NJ Bio

Suven Pharma acquires controlling stake in NJ Bio Inc to strengthen position in US market

Suven Pharmaceuticals strengths its ADC offering with acquisition of NJ Bio

Suven Pharmaceuticals to acquire controlling stake in US-based company NJ Bio

Suven Pharma to acquire majority stake in US-based NJ Bio

Suven Pharma ने अमेरिकी कंपनी NJ Bio में खरीदी 56% हिस्सेदारी; मंडे को शेयर पर रखें पैनी नज़र, 6 महीने में दिया 104% रिटर्न

Suven Pharma to acquire controlling stake in NJ Bio with investment of USD 64.4 million

Suven Pharma to acquire 56% stake in U.S. firm NJ Bio for $64.4 million

Suven Pharma to acquire 56 pc stake in US-based firm for USD 64.4 mn

Suven Pharmaceuticals acquires controlling stake in NJ Bio for USD 64.4 million

Hyderabad's Suven to acquire controlling stake in Princeton based NJ Bio, Inc

Suven Pharma Ranks Among Global Top 20 for Sustainable Growth

Suven Pharmaceuticals Ltd Surges 4.23%

Suven Pharma Standalone September 2024 Net Sales at Rs 236.06 crore, up 5.09% Y-o-Y

Suven Pharmaceuticals - These 4 stocks showing RSI Trending Up on November 13

Suven Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2024

Suven Pharma shares jump 6% after topline zooms 11% in Q2 earnings

Suven Pharmaceuticals Q2 Results Live: Profit Rise by 3.33% YOY | Company Business News

Suven Pharmaceuticals Q2 FY25 revenue grows 12% in Q2

Suven Pharma gains as PAT rises to Rs 82 crore in Q2

Suven Pharma Q2 Results: Net profit rises 3% to Rs 82 crore

Suven Pharmaceuticals' Stock Sees Decline, But Remains Strong in Pharmaceutical Industry